Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
A tablet with the two drugs in Epclusa plus voxilaprevir could become the first regimen approved for those who have failed hep C treatment.
This holds true particularly for those who are younger and healthier and those in communities with lower hep C prevalence among users.
Compounding the problem, state prison systems do not have access to the drug discounts that certain federal agencies do.
The black-box warning, which applies to all hep C medications, is the most serious the health agency can give.
Lowering blood pressure also reduces heart attack risk.
A study of European men who have sex with men found that nearly one in three were reinfected within five years.
The designation is granted to treatments that may offer a significant advancement over those currently available.
The misreported news, which originated in The Sunday Times, concerns a “kick-and-kill” cure attempt that still requires years of follow-up...
WATCH: A video and campaign by HIV, hepatitis C and LGBT groups to address the rising costs of meds.
Many had misconceptions in a recent study.
Some who resolved hep B have seen their infection reactivate while on hep C therapy.
Despite the expansion of HIV treatment, rates of end-stage liver disease among those coinfected with hepatitis B or C remain unchanged.
Interim results of a mid-level trial suggest that six or eight weeks of odalasvir, AL-335 and Olysio (simeprevir) work well against hep C.
This disparity is driven by heavy drinking or injection drug use, an indication that changing such behaviors may save lives.
Even those who did not qualify for a treatment shorter than 12 weeks did well on the regimen in a real-world study.
Even light to moderate alcohol consumption is associated with developing liver cancer.